Plexium

We are thrilled to welcome Serge Messerlian of DCVC to the Plexium board of directors! Serge brings over 25 years of biotech experience to our board, with a proven track record in company building, executive leadership in R&D and large pharma companies, strategic planning and fundraising. https://lnkd.in/gE-_An6b

Next week, our Chief Financial Officer, Stephen Mullennix, is scheduled to present at the Oppenheimer & Co. Inc. 34th Healthcare Conference virtually on Tuesday, February 13th, at 12 pm ET. Plexium management will also participate in one-on-one meetings with investors during the conference.   #OPCOLifeScience #biopharma #TPD #proteindegradation

2024 is off to a great start at Plexium. We recently initiated the PLX-4545 Phase 1 study; we continue to advance our preclinical pipeline of monovalent degraders of SMARCA2, CDK2 and c-Raf; and today, we announced the appointment of Michael Martin, Ph.D. as President and CEO. Read our full press release to learn more about Plexium and our mission: https://lnkd.in/gxUcSg2B #tpd #drugdiscovery #pharma #biotech

We are thrilled to announce the appointment of Michael Martin, Ph.D. as our new President and CEO. Michael is a seasoned scientific executive and global R&D leader, who joins us following a 12-year tenure at Takeda Pharmaceuticals.  His expertise in research & development activities, business development, and venture investment positions him perfectly to lead Plexium into a new era of growth. Learn more about this exciting news here: https://lnkd.in/gxUcSg2B #tpd #drugdiscovery #pharma #biotech

Plexium is pleased to announce that the first subjects have been dosed in a Phase 1 study of PLX-4545, a potent and selective molecular glue degrader of IKZF2, a classically undruggable transcription factor. Initiation of this study represents an important milestone for Plexium, as PLX-4545 is our first small molecule degrader program stemming from our proprietary drug discovery platform to enter human studies. Learn more here: https://bit.ly/3Nnsfr2   #tpd #drugdiscovery #drugdesign #pharma #biotech

Last week, our Plexium team joined forces for a volunteer day at the Jacobs & Cushman San Diego Food Bank. Together with other group, we packed an incredible 10,221 pounds of fruit, destined to make a difference in the lives of families in need. And after our meaningful work, we gathered for a heartwarming Thanksgiving feast! #graditude #makingadifference

Today, Stephen Mullennix, our Chief Financial Officer, is attending the Bank of America Healthcare Trailblazers Private Company Conference and will be participating in one-on-one meetings with investors during the conference. #biopharma #TPD #proteindegradation #science

At our recent Science Day, Plexium’s talented scientists and technologists shared examples of their innovative work with colleagues from across the company. A highlight of Science Day was a poster session featuring 21 posters demonstrating Plexium's advancements in chemistry, biology, screening, proteomics, and technology. Collaboration and shared learning are integral to our scientific culture at Plexium, and we were thrilled by the engagement of our colleagues across the entire company. Learn more about Plexium here. https://www.plexium.com/ #tpd #proteindegradation #drugdiscovery #drugdesign #pharma #biotech #discoveryontarget #sandiegobiotech #scienceday

At our recent Science Day, Plexium’s talented scientists and technologists shared examples of their innovative work with colleagues from across the company. A highlight of Science Day was a poster session featuring 21 posters demonstrating Plexium's advancements in chemistry, biology, screening, proteomics, and technology. Collaboration and shared learning are integral to our scientific culture at Plexium, and we were thrilled by the engagement of our colleagues across the entire company. Learn more about Plexium here: https://www.plexium.com/ #drugdiscovery #drugdesign #pharma #biotech #discoveryontarget #sandiegobiotech #scienceday #tpd #proteindegradation

Last week, Plexium celebrated Science Day, a special event where our talented scientists and technologists gathered to share their innovative work with colleagues from across the company. As part of Science Day, our summer interns presented their accomplishments at Plexium, representing disciplines from Medicinal and Computational Chemistry, Proteomics, Software Engineering, and Discovery Technology. Our Intern program plays a crucial role in nurturing the next generation of scientists, and we wish all our interns the best in their future studies. Learn more about Plexium here. https://www.plexium.com/ #tpd #proteindegradation #drugdiscovery #drugdesign #pharma #biotech #discoveryontarget #sandiegobiotech #summerinterns Hunter Schaffer, Gayathri Donepudi, Kristina Ivanov, Karthyayani Sajeev, Hieu Pham, Daphne Huanca-vargas